NL-OMON26478招募中不适用
An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.
niversity Medical Center0 个研究点目标入组 55 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Written informed consent;
- •2. Age ≥ 18 years;
排除标准
- •1. Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible;
- •2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal
- •carcinomatosis, except for individuals who have previously-treated CNS metastases, are
- •asymptomatic, with no radiological signs of progression and have had no requirement for
- •steroids or anti-seizure medication for 6 months prior to first dose of study drug;
研究者
相似试验
已完成
2 期
An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.endometrial canceruterine corpus carcinoma10046828NL-OMON39290Academisch Medisch Centrum55
已完成
2 期
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing BevacizumabLung CancerNCT01262820UNC Lineberger Comprehensive Cancer Center15
已完成
1 期
Trial of PAZOpanib with or without FOSbretabulin in advanced recurrent ovarian cancerCancerISRCTN30090285The Christie NHS Foundation Trust (UK)33
进行中（未招募）
1 期
A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11platinum resistant or refractory ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130EUCTR2009-016151-21-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE72
进行中（未招募）
1 期
An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancerPart I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Stage IIIB wet (with histologically- or cytologically-confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1 Level: LLT Classification code 10029521 Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-010571-24-GBGlaxoSmithKline Research & Development Limited